Partnering
Strategic collaborations to advance BT-924.
Elaphron is open to strategic collaborations to advance the development of BT-924 and related metabolic disease programs.
Areas of interest
Where we partner.
Co-development
Advance BT-924 across indications and geographies.
Combination strategy
Pair BT-924 with complementary metabolic therapies.
Translational research
Joint preclinical and early clinical programs.
Regional licensing
Selective licensing in defined territories.